Single dose (Johnson & Johnson)

URI: https://gptkb.org/entity/Single_dose_(Johnson_&_Johnson)
GPTKB entity
Statements (44)
Predicate Object
gptkbp:instanceOf vaccine
gptkbp:age 18 and older
gptkbp:antigen gptkb:SARS-CoV-2_spike_protein
gptkbp:boosterInterval 2 months after initial dose
gptkbp:boosterRecommended yes
gptkbp:CDCRecommendation prefer mRNA vaccines over Janssen
gptkbp:clinicalTrialPhase gptkb:ENSEMBLE_trial
gptkbp:containsAdjuvant no
gptkbp:containsPreservatives no
gptkbp:containsStabilizer yes
gptkbp:countryOfOrigin gptkb:Netherlands
gptkb:United_States
gptkbp:dateOfFirstApproval 2021-02-27
gptkbp:doseVolume 0.5 mL
gptkbp:dosingRegimen single dose
gptkbp:efficacyAgainstSevereDisease 85%
gptkbp:emergencyServices gptkb:European_Union
gptkb:United_States
gptkb:World_Health_Organization
https://www.w3.org/2000/01/rdf-schema#label Single dose (Johnson & Johnson)
gptkbp:manufacturer gptkb:Janssen_Pharmaceuticals
gptkbp:officialName gptkb:Janssen_COVID-19_Vaccine
gptkbp:parentCompany gptkb:Johnson_&_Johnson
gptkbp:pregnancyCategory consult healthcare provider
gptkbp:regulates gptkb:emergency_use_authorization
gptkbp:routeOfAdministration intramuscular injection
gptkbp:sideEffect fever
fatigue
headache
muscle pain
rare blood clotting events
gptkbp:storage 2–8°C
gptkbp:storageStability 3 months at 2–8°C
gptkbp:suspensionDateUS 2021-04-13
gptkbp:suspensionLiftedUS 2021-04-23
gptkbp:suspensionReasonUS rare blood clotting events
gptkbp:target gptkb:COVID-19
gptkbp:technology non-replicating adenovirus vector
gptkbp:type viral vector vaccine
gptkbp:vectorFor human adenovirus serotype 26
gptkbp:website https://www.janssencovid19vaccine.com/
gptkbp:WHOEmergencyUseListing 2021-03-12
gptkbp:bfsParent gptkb:COVID-19_Vaccine
gptkbp:bfsLayer 6